BR100 Increased By (0.02%)
BR30 Increased By (0.06%)
KSE100 Decreased By (-0%)
KSE30 Increased By (0.05%)
BECO 5.52 Decreased By ▼ -0.02 (-0.36%)
BML 56.70 Decreased By ▼ -0.39 (-0.68%)
BOP 35.20 Decreased By ▼ -0.01 (-0.03%)
CNERGY 8.15 Decreased By ▼ -0.05 (-0.61%)
DCL 11.61 Decreased By ▼ -0.03 (-0.26%)
FCCL 56.61 Increased By ▲ 0.12 (0.21%)
FCSC 5.38 Increased By ▲ 0.06 (1.13%)
FFL 17.95 Decreased By ▼ -0.11 (-0.61%)
FNEL 1.29 No Change ▼ 0.00 (0%)
HUMNL 11.10 Decreased By ▼ -0.09 (-0.8%)
KEL 8.39 Increased By ▲ 0.19 (2.32%)
KOSM 6.63 Decreased By ▼ -0.04 (-0.6%)
MLCF 101.06 Increased By ▲ 0.30 (0.3%)
NBP 202.44 Decreased By ▼ -0.56 (-0.28%)
PACE 11.42 Decreased By ▼ -0.07 (-0.61%)
PAEL 43.32 Increased By ▲ 0.24 (0.56%)
PIAHCLA 27.24 Increased By ▲ 0.24 (0.89%)
PIBTL 17.82 Decreased By ▼ -0.02 (-0.11%)
PPL 244.79 Increased By ▲ 2.16 (0.89%)
PRL 35.71 Decreased By ▼ -0.16 (-0.45%)
PTC 65.45 Decreased By ▼ -0.40 (-0.61%)
SEARL 93.55 Decreased By ▼ -0.03 (-0.03%)
SSGC 32.98 Increased By ▲ 0.75 (2.33%)
TELE 9.04 Decreased By ▼ -0.07 (-0.77%)
THCCL 66.80 Increased By ▲ 0.31 (0.47%)
TPLP 10.85 Decreased By ▼ -0.10 (-0.91%)
TREET 25.48 Decreased By ▼ -0.24 (-0.93%)
TRG 65.90 Decreased By ▼ -0.05 (-0.08%)
WAVES 11.13 Decreased By ▼ -0.03 (-0.27%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
World

Argentine regulator OK's Sputnik coronavirus vaccination for people over 60

  • The National Administration of Medicines, Food and Medical Technology, or ANMAT, Argentina's regulatory body.
  • the vaccine "is within an acceptable margin of safety and efficacy for the age group over 60 years."
Published January 20, 2021 Updated January 20, 2021 09:48pm
By

BUENOS AIRES: Argentina has approved use of Russia's Sputnik coronavirus vaccination for people over the age of 60, the government of the South American country announced in a statement on Wednesday.

The National Administration of Medicines, Food and Medical Technology, or ANMAT, Argentina's regulatory body, said in the statement that the vaccine "is within an acceptable margin of safety and efficacy for the age group over 60 years."

Comments

Comments are closed for this article.